Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 12, 2025
Discovery & Translation
Science Spotlight: Killing the mesenchymal precursors that drive cancer progression
BioCentury’s roundup of translational innovations also includes blood detection of pregnancy complications, BBB-crossing antibodies, and more
BioCentury | Apr 26, 2024
Emerging Company Profile
Visgenx: Taking retinal gene therapy beyond rare disease
First program delivers an enzyme involved in the fatty acid synthesis pathway for patients with dry AMD
BioCentury | Nov 9, 2023
Regulation
Nov. 8 Quick Takes: FDA approves Lilly’s tirzepatide for weight loss
Plus: Takeda’s fruquintinib approved for colorectal cancer, and updates from Forward, Ascidian, Xencor, UltraDx and more
BioCentury | Jun 5, 2023
Product Development
As Vertex founder Boger returns, long-simmering Alkeus draws $150M for Stargardt program
After subsisting for more than a decade on very little cash, tiny biotech believes registrational data point way to building a larger company
BioCentury | Mar 23, 2023
Discovery & Translation
Deep learning for antimicrobial peptides; plus Zymeworks’ anti-HER2 bispecific and more
BioCentury's roundup of translational news
BioCentury | Oct 12, 2022
Emerging Company Profile
Ascidian: correcting mutations via trans-splicing to edit RNA exons
ATP’s $50M series A will help advance a lead ophthalmic program
BioCentury | May 13, 2022
Data Byte
Distillery spotlight on Italian innovation
Opportunities include compounds and targets for cancer, neurology and musculoskeletal diseases, and discoveries from company founders
BioCentury | Feb 16, 2022
Emerging Company Profile
Splice Bio: gene therapies that reassemble large proteins in vivo
Spain’s largest-ever biotech series A goes to Ysios-backed Splice Bio, which uses inteins to reconstitute large proteins
BioCentury | Jul 21, 2021
Finance
French gene therapy play Coave rebrands with €21.2M series B extension
Formerly Horama, Coave is developing targeted therapies for CNS, ocular diseases
BioCentury | May 28, 2019
Distillery Therapeutics
Split intein-based gene therapies for two types of congenital blindness
Items per page:
1 - 10 of 31